Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / *W EXP 99/99/999
-
Number of holders
-
11
-
Total 13F shares, excl. options
-
1.32M
-
Shares change
-
-10.7K
-
Total reported value, excl. options
-
$18.8M
-
Value change
-
+$116K
-
Number of buys
-
3
-
Number of sells
-
-3
-
Price
-
$14.25
Significant Holders of NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) as of Q4 2024
14 filings reported holding NAMSW - NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 as of Q4 2024.
NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) has 11 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.32M shares
.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (500K shares), RA CAPITAL MANAGEMENT, L.P. (333K shares), Affinity Asset Advisors, LLC (238K shares), Bain Capital Life Sciences Investors, LLC (100K shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (92.8K shares), Laurion Capital Management LP (16.7K shares), HRT FINANCIAL LP (13.7K shares), WOLVERINE ASSET MANAGEMENT LLC (12.7K shares), Vestcor Inc (9.63K shares), and UBS Group AG (2.48K shares).
This table shows the top 11 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.